3. Development trend of clinical immunotherapy based on DC and T
cells
Currently, immune checkpoint inhibitors have been widely used in
clinical cancer treatments and are an important treatment for advanced
NSCLC. CAR-T has emerged as a genuine modality for treating blood
tumors. However, their low efficacy in treating solid tumors limits
their application. Although it has been reported, it is still in the
exploratory stage [103-104]. In combination with
the clinical application of immunotherapy and advances made in
understanding immune cells, especially DC, the trend of next-generation
immunotherapy is moving towards developing artificial DC and CAR-T that
can be used to treat solid tumors. Both can override the limitation of
low immunity in tumor patients.